ELICIO THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.67 USD | -0.27% |
|
-10.71% | -56.00% |
| Jul. 01 | Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell Microcap Growth Index | CI |
| Jul. 01 | Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell 3000E Index | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 80.11 | 39.47 | - | - |
| Enterprise Value (EV) 1 | 80.11 | 39.47 | 39.47 | 39.47 |
| P/E ratio | - | - | - | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 9,606 | 10,755 | - | - |
| Reference price 2 | 8.340 | 3.670 | 3.670 | 3.670 |
| Announcement Date | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -35.74 | -42.85 | -48.54 | -62.29 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | -28.21 | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | -1.620 | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/29/23 | 3/29/24 | - | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -10.77 | -9.392 | -10.24 | -10.51 | -10.86 | -11.24 | -10.81 | -11 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/23 | 3/29/24 | 5/15/24 | - | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | 0.07 | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/29/23 | 3/29/24 | - | - | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.67
USD
Average target price
10
USD
Spread / Average Target
+172.48%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -56.00% | 37.74M | |
| +18.97% | 44.44B | |
| +41.98% | 40.03B | |
| -10.06% | 37.68B | |
| +31.15% | 31.46B | |
| -7.79% | 27.29B | |
| +13.32% | 26.29B | |
| +43.05% | 13.8B | |
| +31.28% | 12.46B | |
| -7.41% | 11.26B |
- Stock Market
- Equities
- ELTX Stock
- Financials Elicio Therapeutics, Inc.
